Quantcast

Latest Aeterna Zentaris Inc. Stories

2014-04-01 08:28:18

QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California. Abstract#3711: "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and...

2014-03-20 16:26:50

All amounts are in US dollars QUEBEC CITY, March 20, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2013. Revenues for the year ended December 31, 2013 were $6.2 million compared to $2.1 million for the same period in...

2014-03-12 08:30:01

QUEBEC CITY, March 12, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by...

2014-02-04 08:34:07

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article,...

2014-02-03 08:27:19

QUÉBEC CITY, Feb. 3, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11(th) International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014. The session will be held on Tuesday, February 11, 2014, in Hall A of the Wyndham Hotel in Salzburg. Presentations are scheduled as follows:...

2014-01-14 12:27:21

QUÉBEC CITY, Jan. 14, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the closing of its previously announced public offering of 11.0 million units (the "Offering") generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise...

2014-01-09 08:28:27

QUÉBEC CITY, Jan. 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the pricing of its previously announced public offering of 11.0 million units (the "Offering"), with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant will be exercisable for a period of five years following the issuance thereof at an exercise price of US$1.25 per...

2014-01-08 16:26:37

QUÉBEC CITY, QC, Jan. 8, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has commenced an underwritten public offering of units (the "Offering"), consisting of common shares and warrants to purchase common shares. The pricing and number of Units as well as the exercise price and duration of the warrants will be determined in the course of marketing. Canaccord Genuity is acting as sole book-running manager for the...

2014-01-06 12:28:21

QUEBEC CITY, Jan. 6, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the Company's New Drug Application ("NDA") for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency ("AGHD"). The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review. The...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related